MiraVista Diagnostics, a developer of diagnostic tests for fungal diseases, announced Thursday morning that it plans to invest $5.3 million to expand its Indianapolis headquarters, creating up to 31 jobs by 2021.
The company, which currently has 44 full-time employees, said it will double the size of its headquarters at 4705 Decatur Blvd. near Indianapolis International Airport to 48,000 square feet. The additional space will allow MiraVista to expand its infectious-disease laboratory, broaden the number of diseases it tests for and scale up the R&D and production of in vitro diagnostic devices.
“The city of Indianapolis and Decatur Township have been great places to grow and provide diagnostic testing services both nationally and globally,” Dr. Lawrence Joseph Wheat, who founded MiraVista in 2002, said in a written statement.
The company, which processes more than 100,000 fungal-infection tests annually, will begin hiring in 2019 for customer service representatives, laboratory technicians, research scientists and sales and marketing employees.
The Indiana Economic Development Corp. offered MiraVista up to $275,000 in tax credits and $50,000 in training grants based on its job-creation plans. The incentives are performance-based, meaning the company can’t claim them until workers are hired.
In addition, the city of Indianapolis plans to offer a six-year real property tax abatement.
Last year, MiraVista received a $582,312 Phase 1 research grant from the National Institutes of Health as part of the Small Business Innovation Research program. In addition, the company worked with the Indiana Procurement Technical Assistance Center and Elevate Ventures to secure a $50,000 SBIR matching grant.